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Abstract
Background: There have been concerns that low blood cholesterol concentrations may cause non-
vascular mortality and morbidity. Randomisation of large numbers of people to receive a large, and
prolonged, reduction in cholesterol concentrations provides an opportunity to address such concerns
reliably.
Methods: 20,536 UK adults (aged 40–80 years) with vascular disease or diabetes were randomly allocated
to receive 40 mg simvastatin daily or matching placebo. Prespecified safety analyses were of cause-specific
mortality, and of total and site-specific cancer incidence. Comparisons between all simvastatin-allocated
versus all placebo-allocated participants (ie, "intention-to-treat") involved an average difference in blood
total cholesterol concentration of 1.2 mmol/L (46 mg/dL) during the scheduled 5-year treatment period.
Results: There was a highly significant 17% (95% CI 9–25) proportional reduction in vascular deaths, along
with a non-significant reduction in all non-vascular deaths, which translated into a significant reduction in
all-cause mortality (p = 0.0003). The proportional reduction in the vascular mortality rate was about one-
sixth in each subcategory of participant studied, including: men and women; under and over 70 years at
entry; and total cholesterol below 5.0 mmol/L or LDL cholesterol below 3.0 mmol/L. No significant excess
of non-vascular mortality was observed in any subcategory of participant (including the elderly and those
with pretreatment total cholesterol below 5.0 mmol/L), and there was no significant excess in any
particular cause of non-vascular mortality.
Cancer incidence rates were similar in the two groups, both overall and in particular subcategories of
participant, as well as at particular primary sites. There was no suggestion that any adverse trends in non-
vascular mortality or morbidity were beginning to emerge with more prolonged treatment.
Conclusion: These findings, which are based on large numbers of deaths and non-fatal cancers, provide
considerable reassurance that lowering total cholesterol concentrations by more than 1 mmol/L for an
average of 5 years does not produce adverse effects on non-vascular mortality or cancer incidence.
Moreover, among the many different types of high-risk individual studied, simvastatin 40 mg daily
consistently produced substantial reductions in vascular (and, hence, all-cause) mortality, as well as in the
rates of non-fatal heart attacks, strokes and revascularisation procedures.
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Background
Observational studies have found blood total cholesterol
concentrations below about 4.0 mmol/L (155 mg/dL) to
be associated with higher rates of mortality and morbidity
from certain non-vascular causes (in particular, cancer of
lung, liver, pancreas and blood; chronic obstructive pul-
monary disease; cirrhosis; suicide; and haemorrhagic
stroke) [1,2]. Excluding events within the first few years
after the baseline measurement of cholesterol attenuates
some, but not all, of these associations. It remains unclear,
however, whether these inverse associations are causal
(with low cholesterol actually causing certain diseases), or
instead due to confounding or reverse causation (with cer-
tain habits or conditions independently causing both
lower cholesterol and disease) [3,4]. Randomised trials
are not subject to such biases, but the trials of cholesterol-
lowering interventions before the statins were unable to
assess causation reliably, chiefly because they involved
too few non-vascular outcomes (even in combination)
and assessed only modest cholesterol reductions from
high pretreatment concentrations [5,6]. Some slight
excesses of non-vascular deaths or cancers in particular tri-
als provoked much comment over the years, contributing
to the uncertainty that surrounded cholesterol-lowering
[7-11].
More recently, in previous trials of statin treatment, LDL
cholesterol was typically reduced by about 1.0 mmol/L
(38 mg/dl) and major vascular events reduced by about
25% [12-19]. Although meta-analyses of those trials indi-
cate that statin therapy reduces vascular mortality [20-23],
the secondary prevention trials involved few deaths from
non-vascular causes [12-15], and the primary prevention
trials involved relatively few deaths from any cause [16-
19]. Moreover, these trials provided relatively little infor-
mation about the effects of lowering total cholesterol to
the low concentrations (e.g. around 4.0 mmol/L) that had
previously raised concerns. By contrast, the Heart Protec-
tion Study (HPS) involved large numbers of deaths from
both vascular and non-vascular causes among people pre-
senting with below-average cholesterol levels who were
randomly allocated to have their cholesterol lowered sub-
stantially for several years [24]. Consequently, it allows
outstanding concerns about the potential hazards of low-
ering cholesterol to be addressed much more reliably than
has previously been possible. The present report provides
detailed information about the effects of lowering choles-
terol on cause-specific mortality, site-specific cancer inci-
dence and other major morbidity in a range of different
circumstances.
Methods
Details of HPS have been reported previously [24-29] (see
also http://www.hpsinfo.org) and are summarised below.
Recruitment and follow-up
Men and women aged about 40 to 80 years with non-fast-
ing blood total cholesterol concentrations of at least 3.5
mmol/L (135 mg/dL) were eligible provided they had a
medical history of: occlusive arterial disease; diabetes mel-
litus; or treated hypertension (if also male and aged at
least 65 years). People were ineligible if their own doctor
considered statin therapy to be clearly indicated or con-
traindicated, or if they had a past history of: stroke, myo-
cardial infarction or angina hospitalisation within the
previous 6 months; chronic liver disease or evidence of
abnormal liver function; severe renal disease or evidence
of substantially impaired renal function; inflammatory
muscle disease or evidence of muscle problems; concur-
rent treatment with cyclosporin, fibrates or high-dose
niacin; child-bearing potential; severe heart failure; life-
threatening conditions other than vascular disease or dia-
betes (including any cancer except non-melanoma skin
cancer); or any other condition that might limit long-term
compliance.
Eligible and consenting patients entered a pre-randomisa-
tion "run-in" treatment phase, which involved 4 weeks of
placebo followed by 4–6 weeks of 40 mg simvastatin
daily. Compliant individuals who were still not consid-
ered by their own doctors to have a clear indication for, or
contraindication to, statin therapy were then randomly
allocated to receive 40 mg simvastatin daily or matching
placebo tablets for about 5 years (and separately, using a
2 × 2 factorial design, to receive antioxidant vitamins or
matching placebo capsules [29]). Randomised partici-
pants were to be seen at 4, 8 and 12 months, and then 6-
monthly (with follow-up by telephone for individuals
who did not attend or, alternatively, via their general prac-
titioner). Compliance with study treatment was assessed
by questioning participants and reviewing the calendar-
packed tablets remaining. Blood samples were taken at
each follow-up visit for central laboratory assay of alanine
transaminase to monitor liver function, and of creatine
kinase in any participant reporting unexplained muscle
symptoms or concomitant use of a non-study statin. To
assess the effects of the treatment allocation on the lipid
profile, assays were performed on non-fasting blood col-
lected from a sample of participants due for follow-up at
about the same time each year, and from all participants
attending follow-up at an average of 4.6 years. Differences
in average blood lipid concentrations were based on com-
parisons between all those allocated simvastatin and all
those allocated placebo, irrespective of whether or not
they were still compliant.
Information was recorded at each follow-up about any
suspected myocardial infarction, stroke, vascular proce-
dure, cancer or other serious adverse experience, and
about the main reasons for all other hospital admissions.BMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
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UK national registries provided information about the
sites of any registered cancers and the certified causes of
death. Further details were sought from general practition-
ers (and, if considered necessary, hospital records) about
all reports that might relate to major vascular events, can-
cers (e.g. investigations) or deaths. All such information
was coded according to prespecified criteria by coordinat-
ing centre clinical staff, who were unaware of the partici-
pants' study treatment allocation. Analyses were based on
confirmed plus unrefuted reports of events. Cancers were
classified according to their primary anatomical site rather
than their histology (except that skin cancers were sub-
classified as melanoma or non-melanoma), with definite
confirmation for 98% of the included cancers. Mortality
follow-up was available for 99.7% of participants, with
certified causes for 98.2% of deaths.
Statistical analyses
The main comparisons involved logrank analyses of the
first occurrence of particular events during the scheduled
treatment period among all those allocated simvastatin
versus all those allocated matching placebo tablets (i.e.
"intention-to-treat"). These logrank analyses yielded both
the event rate ratio (RR) and the test of statistical signifi-
cance (two-sided probability value). The prespecified pri-
mary comparisons were of the effects of allocation to
simvastatin on deaths from all causes and, separately, on
deaths from all coronary causes and from all non-coro-
nary causes. But since simvastatin appeared to reduce the
risk of death not only from coronary causes but also from
other vascular causes (as well as preventing non-fatal vas-
cular events) [24], the present analyses are of all vascular
deaths and of all non-vascular deaths.
Prespecified secondary comparisons included the effects
of simvastatin allocation on specific vascular and non-vas-
cular causes of death [25], with due allowance made in
their interpretation for multiple hypothesis testing, for the
effects observed on relevant non-fatal events, and for evi-
dence from other studies. It was not anticipated that there
would be adequate statistical power to assess the effects of
study treatment on vascular or total mortality directly in
different circumstances. Instead, the prespecified compar-
isons involved assessment of the effects on major coro-
nary events (defined as non-fatal myocardial infarction or
coronary death), and on the even larger numbers of major
vascular events (i.e. major coronary event, stroke or arte-
rial revascularisation), in the first two years and in the
later years of scheduled treatment (in order to determine
whether any protective effect increases with time), and in
various prespecified subcategories determined at study
entry, including: sex; age (<65; ≥ 65<70; ≥ 70 years); and
pretreatment plasma concentrations of total cholesterol
(<5.0; ≥ 5.0<6.0; ≥ 6.0 mmol/L) and of LDL cholesterol
(<3.0; ≥ 3.0<3.5; ≥ 3.5 mmol/L). Pre-specified tertiary com-
parisons included the effects on vascular mortality sepa-
rately during years 1–2 and years 3+ of follow-up, on
cause-specific mortality in the prespecified subcategories
of pretreatment total cholesterol, and on site-specific can-
cer incidence and cerebral haemorrhage. Tests for hetero-
geneity or, if more appropriate, trend were to be used to
assess whether the proportional effects observed on par-
ticular outcomes in specific subcategories differed clearly
from the overall effect (after due allowance for multiple
comparisons).
Role of the funding sources
The investigators were responsible for the study design,
data collection, data analysis, data interpretation, and




A total of 20,536 individuals were randomised between
July 1994 and May 1997. Mean age at study entry was 64.0
years (SD 8.4), with 5806 aged at least 70 years. Prior to
any statin treatment being started, participants who were
subsequently randomised had mean non-fasting plasma
concentrations of total cholesterol of 5.9 mmol/L (SD
1.0), directly-measured LDL cholesterol of 3.4 mmol/L
(0.8), HDL cholesterol of 1.06 mmol/L (0.3) and triglyc-
erides of 2.1 mmol/L (1.4). There were 4072 randomised
participants whose pretreatment measurements of total
cholesterol were below 5.0 mmol/L (193 mg/dL) and
6793 with pretreatment LDL cholesterol below 3.0 mmol/
L (116 mg/dL). The large size of the study (and the use of
minimised randomisation [30]) produced good balance
between the treatment groups for the main prognostic fea-
tures that were measured (see subcategory figures below),
and should have done likewise for those that were not.
Compliance and effects on blood lipids
The mean duration of follow-up was 5.0 years for all ran-
domised participants: 5.3 years for those who survived to
the scheduled end of study treatment and about half that
for those who did not (yielding 51,121 person years of
follow-up for all those allocated simvastatin and 50,664
for all those allocated placebo). Compliance at each fol-
low-up was defined as at least 80% of the scheduled sim-
vastatin or placebo tablets having been taken since the
previous follow-up. Among the participants allocated 40
mg simvastatin daily, average statin use during the sched-
uled treatment period was 85% (with 82% compliant
with their allocated simvastatin, 3% on non-study statin
alone and 2% on both). By contrast, among those allo-
cated placebo, 4% at the end of the first year of follow-up,
but 32% at the end of the fifth year, were taking non-study
statin therapy, yielding an average of 17%. Non-study sta-
tin use in the placebo group was more common amongBMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
Page 4 of 21
(page number not for citation purposes)
those who already had diagnosed coronary disease at
entry, were younger or had higher pretreatment total or
LDL cholesterol concentrations [24]. In each subcategory
studied, however, the average difference in total choles-
terol was about 1.2 mmol/L (range: 1.1–1.3 mmol/L:
table 1) and in LDL cholesterol was about 1.0 mmol/L
(range: 0.9–1.1 mmol/L). In particular, among the 4072
participants whose pretreatment measurements of total
cholesterol were below 5.0 mmol/L (193 mg/dL), the
average total cholesterol concentration during the trial
was 3.5 mmol/L in the simvastatin group compared to 4.6
mmol/L in the placebo group.
Effects on vascular mortality and morbidity
Overall, allocation to simvastatin produced a highly sig-
nificant 17% (SE 4; p < 0.0001) proportional reduction in
vascular mortality during the 5 years of the study (table 2).
This reflected a definite 18% (SE 5; p = 0.0005) reduction
in deaths due to coronary causes, together with a non-sig-
nificant 20% (SE 12; p = 0.1) reduction in fatal strokes
and 12% (SE 13; p = 0.3) reduction in deaths from other
vascular causes, with no significant difference between the
effects observed on these different vascular causes (heter-
ogeneity p = 0.9). Among the coronary causes there were
also no statistically significant differences among the
effects of statin allocation on deaths attributed to acute
myocardial infarction, sudden death, heart failure second-
ary to coronary disease, or other coronary causes (hetero-
geneity p = 0.5). There was no apparent difference
between the treatment groups in the small number of
deaths attributed to cerebral haemorrhage, whereas there
was a non-significant reduction in fatal strokes due to
ischaemic (or unknown) causes. Other vascular causes
comprised deaths from peripheral vascular disease (which
included ruptured aortic aneurysm) and from a variety of
other cardiac conditions (including a few attributed to
heart failure), again with no significant heterogeneity in
the effects of simvastatin allocation on these different
causes of death (heterogeneity p = 0.7).
The apparent reductions in different types of vascular
death with allocation to simvastatin are reinforced by
more definite effects on the larger numbers of non-fatal
and fatal vascular events considered together. For exam-
ple, the very definite 27% (SE 4; p < 0.0001: figure 1)
reduction in first non-fatal myocardial infarction or
Table 1: Average plasma total and LDL cholesterol concentrations during follow-up
Baseline 
characteristic
Plasma total cholesterol (mmol/l) Plasma LDL cholesterol (mmol/l)
Simvastatin Placebo Difference* Simvastatin Placebo Difference*
Sex
Male 4.1 5.3 -1.2 2.2 3.2 -1.0
Female 4.6 5.8 -1.2 2.5 3.4 -0.9
Age (years)
<65 4.3 5.4 -1.1 2.4 3.2 -0.9
≥ 65 <70 4.1 5.4 -1.3 2.2 3.3 -1.0




<5.0 3.5 4.6 -1.1 1.8 2.6 -0.9
≥ 5.0 <6.0 4.0 5.2 -1.2 2.1 3.1 -1.0
≥ 6.0 4.8 6.0 -1.2 2.7 3.7 -1.0
LDL cholesterol 
(mmol/L)
<3.0 3.7 4.9 -1.1 1.8 2.7 -0.9
≥ 3.0 <3.5 4.1 5.3 -1.2 2.2 3.2 -1.0
≥ 3.5 4.7 5.9 -1.2 2.7 3.7 -1.0
ALL PATIENTS 4.2 5.4 -1.2 2.3 3.3 -1.0
* Intention-to-treat comparisons with missing data imputed from initial pre-treatment screening values. The absolute difference in LDL-cholesterol 
that would be produced by full compliance with 40 mg simvastatin daily can be estimated as the ratio of the absolute difference to the estimated 
compliance. For example, -1.0/67% = -1.5 mmol/L.BMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
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coronary death (i.e. "major coronary events") following
randomisation reinforces the observed effect on coronary
death [24]. Similarly, the definite 25% (SE 5; p < 0.0001)
reduction in first non-fatal or fatal stroke following ran-
domisation (444 [4.3%] simvastatin versus 585 [5.7%]
placebo) indicates that the trend toward fewer fatal
strokes with simvastatin is likely to be real [28]. Despite
concerns about possible adverse effects of statin therapy
on heart failure [31], the non-significant trend toward
fewer heart failure deaths due to any cause (70 [0.7%] vs
86 [0.8%]; RR 0.81 [0.59–1.10]; p = 0.2) is supported by
a marginally significant reduction in first hospital admis-
sion for worsening heart failure or heart failure death (354
[3.4%] vs 405 [3.9%]; RR 0.86 [0.75–1.00]; p = 0.05).
In this high-risk population with occlusive arterial disease
or diabetes, about 1.5% of placebo-allocated patients died
from vascular causes during each year of follow-up. A
highly significant 24% (95% CI 10–35; p = 0.002) pro-
portional reduction in vascular mortality emerged during
the first two years after the initiation of simvastatin treat-
ment (figure 2), which is reinforced by the prespecified
analyses of major coronary events (figure 1) and of major
vascular events (figure 3). Further reductions in vascular
mortality were observed during the subsequent years of
Table 2: Effect of simvastatin allocation on vascular and non-vascular causes of death








Acute MI 141 (1.4%) 191 (1.9%) 0.73 (0.59 – 0.91)
Sudden death 147 (1.4%) 154 (1.5%) 0.95 (0.75 – 1.19)
Heart failure* 65 (0.6%) 78 (0.8%) 0.82 (0.59 – 1.15)
Other coronary 234 (2.3%) 284 (2.8%) 0.82 (0.69 – 0.97)
Subtotal: Coronary 587 (5.7%) 707 (6.9%) 0.82 (0.74 – 0.92) 0.0005
Stroke
Haemorrhagic 23 (0.2%) 24 (0.2%) 0.95 (0.54 – 1.68)
Ischaemic (or unknown) 73 (0.7%) 95 (0.9%) 0.76 (0.56 – 1.03)
Subtotal: Stroke 96 (0.9%) 119 (1.2%) 0.80 (0.61 – 1.05) 0.1
Other vascular
Peripheral vascular 58 (0.6%) 63 (0.6%) 0.91 (0.64 – 1.30)
Other cardiac* 40 (0.4%) 48 (0.5%) 0.83 (0.54 – 1.25)
Subtotal: Other vascular 98 (1.0%) 111 (1.1%) 0.88 (0.67 – 1.15) 0.3
VASCULAR 781 (7.6%) 937 (9.1%) 0.83 (0.75 – 0.91) <0.0001
Neoplastic
Respiratory 127 (1.2%) 133 (1.3%) 0.94 (0.74 – 1.20)
Gastrointestinal 112 (1.1%) 103 (1.0%) 1.08 (0.82 – 1.41)
Genitourinary 47 (0.5%) 46 (0.4%) 1.01 (0.67 – 1.52)
All others 73 (0.7%) 62 (0.6%) 1.17 (0.83 – 1.63)
Subtotal: Neoplastic 359 (3.5%) 345 (3.4%) 1.03 (0.89 – 1.19) 0.7
Other non-vascular
Respiratory 90 (0.9%) 114 (1.1%) 0.78 (0.59 – 1.03)
Gastrointestinal 35 (0.3%) 41 (0.4%) 0.85 (0.54 – 1.33)
Other medical† 47 (0.5%) 49 (0.5%) 0.95 (0.64 – 1.42)
Non-medical 16 (0.2%) 21 (0.2%) 0.75 (0.40 – 1.44)
NON-VASCULAR 547 (5.3%) 570 (5.6%) 0.95 (0.85 – 1.07) 0.4
ALL DEATHS 1328 (12.9%) 1507 (14.7%) 0.87 (0.81 – 0.94) 0.0003
* Heart failure deaths were subdivided into those considered to be due to coronary disease and those (5 versus 8) due to other vascular (or 
unknown) causes.
† Includes renal, infectious, metabolic, neurological and unknown deaths.BMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
Page 6 of 21
(page number not for citation purposes)
the scheduled treatment period, and again these are rein-
forced by the observed effects on vascular events. About
one third of the placebo-allocated participants were tak-
ing a statin by the end of year 5, and this may account for
the somewhat smaller reductions in vascular deaths (and
vascular events) observed during the later years. Even so,
the continuing reductions in vascular mortality (and mor-
bidity) during each period resulted in increasing absolute
benefits with more prolonged treatment and follow-up
(figure 4). As a consequence, whereas 9.1% of the pla-
cebo-allocated patients died of vascular causes during an
average of 5 years of follow-up, only 7.6% of those allo-
cated simvastatin did so. Hence, lowering LDL cholesterol
by an average of 1.0 mmol/L for 5 years was associated
with the prevention of 14 (SE 5) vascular deaths per 1000
participants.
Figure 5 indicates that the proportional reduction in the
rate of vascular death was about one sixth in various dif-
ferent circumstances, and this pattern is also reinforced by
the prespecified subgroup analyses of the much larger
numbers of major vascular events (figure 6). For example,
there was a 17% (SE 5; p = 0.0004) reduction in vascular
mortality among the 15,454 men and a 19% (SE 11; p =
0.08) reduction among the 5082 women (heterogeneity p
= 0.9 between effect in men vs women), which is rein-
forced by the highly significant reductions in major vascu-
lar events both among men and among women. Similarly,
the proportional reductions in vascular mortality
appeared to be about the same among younger and older
participants (heterogeneity p = 0.9), as was also the case
for major vascular events. But since the older participants
were at higher absolute risk of vascular death, these simi-
lar proportional effects translated into larger absolute
Effect of simvastatin allocation on major coronary events by year of follow-up Figure 1
Effect of simvastatin allocation on major coronary events by year of follow-up. Rate ratios (RR: black squares with 
area proportional to the amount of "statistical information" in each subdivision) comparing outcome among patients allocated 
simvastatin to that among those allocated placebo are plotted, along with their 95% confidence intervals (CI: horizontal lines). 
For relevant subtotals, the result and its 95% CI is represented by a diamond, with the overall proportional reduction and sta-
tistical significance given alongside. Squares or diamonds to the left of the solid vertical line indicate benefit with simvastatin 
(with nominal significance of at least two-sided P < 0.05 when the horizontal line or diamond does not overlap the vertical 
line). The broken vertical lines indicate the overall rate ratios.
Year of Events/people (& %) Event rate ratio & 95% CI
follow-up Simvastatin Placebo (Simvastatin:Placebo)
1   188/10269 (1.8%)   208/10267 (2.0%)
2   162/10022 (1.6%)   226/  9981 (2.3%)
Subtotal: 1 & 2   350/10269 (3.4%)   434/10267 (4.2%) 0.80 (0.70 - 0.92)
p=0.002
3   141/  9759 (1.4%)   235/  9623 (2.4%)
4   152/  9474 (1.6%)   215/  9276 (2.3%)
5+   255/  9161 (2.8%)   328/  8880 (3.7%)
Subtotal: 3+   548/  9759 (5.6%)   778/  9623 (8.1%) 0.69 (0.62 - 0.77)
p<0.0001
ALL FOLLOW-UP   898/10269 (8.7%)  1212/10267 (11.8%) 0.73 (0.67 - 0.79)
p<0.0001
0.6 0.8 1.0 1.2 1.4
Simvastatin better Placebo betterBMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
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benefits at older ages during the 5 year treatment period.
The reduction in vascular mortality also appeared largely
independent of the pretreatment lipid concentrations,
and this pattern is again reinforced by the parallel analyses
of major vascular events.
Effects on non-vascular mortality and morbidity
Overall, there was no evidence that reducing total choles-
terol by an average of 1.2 mmol/L for 5 years produced
any adverse effect on the aggregate of all non-vascular
deaths (RR 0.95 [95% CI 0.85–1.07]; p = 0.4: table 2).
More than half of these non-vascular deaths were due to
cancer, and there were no significant differences between
the treatment groups in the numbers of deaths from all
cancers or from cancers at particular sites (or in the num-
bers of incident cancers: see below). Among participants
allocated simvastatin there were non-significantly fewer
deaths from all respiratory causes, including those due to
Effect of simvastatin allocation on vascular, non-vascular and all-cause mortality by period of follow-up Figure 2
Effect of simvastatin allocation on vascular, non-vascular and all-cause mortality by period of follow-up. Symbols 
and conventions as in Figure 1.
Cause of death & Deaths/people (%) Death rate ratio & 95% CI
follow-up year Simvastatin Placebo (Simvastatin:Placebo)
Vascular death
1 & 2   237/10269 (2.3%)   310/10267 (3.0%)
3 & 4   301/  9907 (3.0%)   369/  9825 (3.8%)
5+   243/  9384 (2.6%)   258/  9229 (2.8%)
VASCULAR   781/10269 (7.6%)   937/10267 (9.1%) 0.83 (0.75 - 0.91)
p<0.0001
Non-vascular death
1 & 2   125/10269 (1.2%)   132/10267 (1.3%)
3 & 4   221/  9907 (2.2%)   225/  9825 (2.3%)
5+   201/  9384 (2.1%)   213/  9229 (2.3%)
NON-VASCULAR   547/10269 (5.3%)   570/10267 (5.6%) 0.95 (0.85 - 1.07)
p=0.4
All deaths
1 & 2   362/10269 (3.5%)   442/10267 (4.3%)
3 & 4   522/  9907 (5.3%)   594/  9825 (6.0%)
5+   444/  9384 (4.7%)   471/  9229 (5.1%)
ALL DEATHS  1328/10269 (12.9%)  1507/10267 (14.7%) 0.87 (0.81 - 0.94)
p=0.0003
0.6 0.8 1.0 1.2 1.4
Simvastatin better Placebo betterBMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
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chronic obstructive pulmonary disease (26 [0.3%] simv-
astatin vs 39 [0.4%] placebo; RR 0.66 [0.41–1.08]; p =
0.1). This apparent lack of any adverse effect on respira-
tory death is reinforced by the similar numbers of partici-
pants in the two treatment groups who either died from,
or were admitted to hospital for, any respiratory illness
(811 [7.9%] simvastatin vs 820 [8.0%] placebo; RR 0.98
[0.89–1.08]; p = 0.7) or for chronic obstructive pulmo-
nary disease (88 [0.9%] vs 110 [1.1%]; RR 0.79 [0.60–
1.05]; p = 0.1). Moreover, lung function assessed by
spirometry in all those attending the final visit showed no
differences between the treatment groups: forced expira-
tory volume in 1 second (FEV1) of 2.06 L simvastatin vs
2.05 L placebo (difference 0.01 L [SE 0.01]; p = 0.5); and
forced vital capacity (FVC) of 2.82 L vs 2.82 L (difference
0.00 L [SE 0.01]; p = 0.9). This was the case even among
participants with pretreatment total cholesterol measure-
ments below 5.0 mmol/L: FEV1 of 2.16 L vs 2.15 L (differ-
ence 0.00 L [SE 0.03]; p = 0.9); and FVC of 2.94 L vs 2.95
L (difference 0.00 [SE 0.03]; p > 0.9).
There were similar numbers of deaths in the two treat-
ment groups from gastrointestinal causes, which included
a small number attributed to liver disease (5 simvastatin
vs 3 placebo). Few patients reported developing cirrhosis
(4 vs 4), but there was no apparent adverse effect on the
much larger number with any non-fatal or fatal liver-
related serious adverse event, either overall (197 [1.9%] vs
200 [1.9%]; RR 0.98 [0.80–1.19]; p = 0.8) or among those
with pretreatment total cholesterol measurements below
5.0 mmol/L (48 [2.4%] vs 41 [2.0%]; RR 1.18 [0.78–
1.78]; p = 0.4). There was also no suggestion of any
adverse effect of cholesterol-lowering therapy on other
medical causes of death (table 2), which included small
numbers due to infections (7 vs 17) and renal disease (10
vs 10). This apparent lack of effect on renal death is rein-
forced by the similar numbers in the two treatment groups
who developed renal failure or died from renal causes (71
[0.7%] vs 63 [0.6%]; RR 1.12 [0.80–1.57]; p = 0.5). Rela-
tively few non-medical deaths occurred, with the majority
being due to accidents and injuries (12 vs 15) and the
remainder due to complications of medical or surgical
procedures (4 vs 5) or suicide (0 vs 1). There was no
apparent excess in the numbers who reported attempted
suicide (14 [0.1%] vs 11 [0.1%]; RR 1.26 [0.58–2.76]; p =
Effect of simvastatin allocation on major vascular events by year of follow-up Figure 3
Effect of simvastatin allocation on major vascular events by year of follow-up. Symbols and conventions as in Figure 
1.
Year of Events/people (& %) Event rate ratio & 95% CI
follow-up Simvastatin Placebo (Simvastatin:Placebo)
1   481/10269 (4.7%)   527/10267 (5.1%)
2   377/  9745 (3.9%)   538/  9683 (5.6%)
Subtotal: 1 & 2   858/10269 (8.4%)  1065/10267 (10.4%) 0.80 (0.73 - 0.87)
p<0.0001
3   359/  9288 (3.9%)   509/  9055 (5.6%)
4   331/  8818 (3.8%)   436/  8463 (5.2%)
5+   485/  8358 (5.8%)   575/  7897 (7.3%)
Subtotal: 3+  1175/  9288 (12.7%)  1520/  9055 (16.8%) 0.74 (0.68 - 0.79)
p<0.0001
ALL FOLLOW-UP  2033/10269 (19.8%)  2585/10267 (25.2%) 0.76 (0.72 - 0.81)
p<0.0001
0.6 0.8 1.0 1.2 1.4
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0.6), development of depression (39 [0.4%] vs 34 [0.3%];
RR 1.14 [0.72–1.80]; p = 0.6) or any psychiatric disorder
(96 [0.9%] vs 90 [0.9%]; RR 1.06 [0.79–1.41]; p = 0.7).
Any adverse effects of lowering cholesterol might be
expected to emerge only after some years of lower choles-
terol levels, but there was no suggestion of an excess of
non-vascular death even during the later years of the study
(figures 2 and 4). For example, there were similar rates of
non-vascular death in each treatment group during years
3 & 4 (RR 0.97 [0.81–1.17]; p = 0.8) and during years 5+
(RR 0.93 [0.77–1.13]; p = 0.5). Nor did lowering total
cholesterol by an average of about 1.2 mmol/L for 5 years
produce an excess of non-vascular mortality in any of the
different types of patient studied (figure 7). For example,
inverse associations between cholesterol concentrations
and mortality have been reported from some observa-
tional studies among the very elderly [32,33]. But no
adverse effect on non-vascular mortality was seen among
the 5806 participants in HPS who were aged 70 years or
older at entry (RR 0.95 [0.80–1.13]; p = 0.6) or, indeed,
even among the 1263 participants who were aged 75–80
Life-table plot of effects of simvastatin allocation on vascular and non-vascular death Figure 4
Life-table plot of effects of simvastatin allocation on vascular and non-vascular death. See figure 2 for numbers of 
participants dying during follow-up.






































Vascular death 1 (2) 7 (2) 11 (3) 14 (3) 14 (5)
Non-vascular death
(logrank p=0.4)
Non-vascular death 1 (1) 1 (2) -1 (2) 1 (3) 3 (4)
Placebo-allocated
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years at entry (60 [9.8%] vs 78 [12.0%]; RR 0.78 [0.56–
1.09]; p = 0.1). Similarly, despite concerns from non-ran-
domised observational studies about higher mortality in
association with low cholesterol concentrations, there was
no adverse effect on non-vascular mortality even among
the 4072 participants with pretreatment total cholesterol
measurements below 5.0 mmol/L (RR 0.99 [0.77–1.26]; p
= 0.9), in whom simvastatin allocation reduced total
cholesterol concentrations to an average of 3.5 mmol/L
(Table 1).
Effects on all-cause mortality
The lack of any overall effect of cholesterol-lowering ther-
apy on non-vascular mortality in different circumstances
(figure 7) suggests that the proportional reduction in all-
cause mortality in any particular circumstance is likely to
depend chiefly on the fraction of deaths that are due to
vascular causes and on the proportional reduction in
vascular mortality that is produced by lowering LDL
cholesterol. For example, in the present study, the 13%
proportional reduction in all-cause mortality produced by
lowering LDL cholesterol by an average of about 1 mmol/
L with statin therapy reflects the combination of the
highly significant 17% reduction in the two-thirds of
deaths due to vascular causes and the lack of any signifi-
cant difference in the remaining one third of deaths from
non-vascular causes (table 2). Figure 2 illustrates this
combined effect on all-cause mortality over time, and the
similar proportional reductions in total mortality in dif-
ferent types of participant (figure 8) reflect the consistent
beneficial effects of simvastatin allocation on vascular
death, and consistent lack of effect on non-vascular
deaths, across subgroups.
Effects on cancer incidence
Overall, there was no evidence that reducing total choles-
terol from an average of 5.4 mmol/L to an average of 4.2
mmol/L (table 1) produced any adverse effect on the
Effect of simvastatin allocation on vascular death in participants subdivided by presenting features Figure 5
Effect of simvastatin allocation on vascular death in participants subdivided by presenting features. Symbols and 
conventions as in Figure 1. P-values for chi-squared tests for heterogeneity across different subgroups are given on the right.
Presenting Simvastatin Placebo Death rate ratio Heterogeneity
feature -allocated -allocated (95% CI) p-value
Gender
Male   653/  7727 (8.5%)   780/  7727 (10.1%) p=0.9
Female   128/  2542 (5.0%)   157/  2540 (6.2%)
Age (years)
<65   223/  4903 (4.5%)   273/  4936 (5.5%) p=0.9
> _65 to <70   219/  2447 (8.9%)   256/  2444 (10.5%)
> _70   339/  2919 (11.6%)   408/  2887 (14.1%)
LDL cholesterol (mmol/L)
<3.0   241/  3389 (7.1%)   285/  3404 (8.4%) p=0.8
> _3.0 to <3.5   180/  2549 (7.1%)   225/  2514 (8.9%)
> _3.5   360/  4331 (8.3%)   427/  4349 (9.8%)
Total cholesterol (mmol/L)
<5.0   145/  2030 (7.1%)   170/  2042 (8.3%) p=0.6
> _5.0 to <6.0   271/  3942 (6.9%)   346/  3941 (8.8%)
> _6.0   365/  4297 (8.5%)   421/  4284 (9.8%)
ALL PATIENTS   781/10269 (7.6%)   937/10267 (9.1%) 0.83 (0.75 − 0.91)
p<0.0001
0.6 0.8 1.0 1.2 1.4
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incidence of first cancer (excluding non-melanoma skin)
at any site following randomisation (814 [7.9%]
simvastatin vs 803 [7.8%] placebo; RR 1.00 [0.91–1.11];
p = 0.9: table 3). Moreover, no significant excess of these
cancers emerged even during the later years of the study
(figure 9). Nor was there any significant evidence that
cholesterol-lowering therapy produced adverse effects on
the cancer incidence rate in any particular type of partici-
pant studied (figure 10). For example, by contrast with a
marginally significant adverse trend in one recently
reported randomised trial of statin therapy [34], simvasta-
tin allocation was not associated with a significant excess
of cancer among the 5806 participants aged 70 years or
older at presentation (RR 1.02 [0.88–1.19]; p = 0.8). Fur-
thermore, whereas non-randomised observational studies
have found higher cancer rates in association with low
cholesterol levels [1,2], no adverse effect was seen on the
cancer incidence rate in this large randomised comparison
among the 4072 participants with pretreatment total cho-
lesterol measurements below 5.0 mmol/L (RR 0.87 [0.71–
1.07]; p = 0.2).
Any adverse effects of cholesterol lowering on cancer
might be expected to be restricted to cancers at particular
sites: for example, respiratory, gastrointestinal and hae-
matological cancers have been associated with low choles-
terol concentrations in observational studies [1,2].
Substantial numbers of respiratory, gastrointestinal and
genitourinary cancers were reported during HPS, so it pro-
vides a reasonably reliable (and unbiased) assessment of
whether lowering cholesterol by more than 1 mmol/L for
about 5 years affects the risks of such cancers. There was
no suggestion of any excess in the incidence of cancers at
these sites, either overall (table 3) or separately among
participants who presented at younger or older age or with
lower or higher cholesterol concentrations (figure 11).
Even in a study of this size, however, too few cancers
occurred at some particular sites (e.g. haematological
Effect of simvastatin allocation on first major vascular event in participants subdivided by presenting features Figure 6
Effect of simvastatin allocation on first major vascular event in participants subdivided by presenting features. 
Symbols and conventions as in Figures 1 & 5.
Presenting Simvastatin Placebo Event rate ratio Heterogeneity
feature -allocated -allocated (95% CI) p-value
Gender
Male  1666/  7727 (21.6%)  2135/  7727 (27.6%) p=0.4
Female   367/  2542 (14.4%)   450/  2540 (17.7%)
Age (years)
<65   831/  4903 (16.9%)  1091/  4936 (22.1%) p=0.6
> _65 to <70   512/  2447 (20.9%)   665/  2444 (27.2%)
> _70   690/  2919 (23.6%)   829/  2887 (28.7%)
LDL cholesterol (mmol/L)
<3.0   598/  3389 (17.6%)   756/  3404 (22.2%) p=0.3
> _3.0 to <3.5   484/  2549 (19.0%)   646/  2514 (25.7%)
> _3.5   951/  4331 (22.0%)  1183/  4349 (27.2%)
Total cholesterol (mmol/L)
<5.0   360/  2030 (17.7%)   472/  2042 (23.1%) p=0.7
> _5.0 to <6.0   744/  3942 (18.9%)   964/  3941 (24.5%)
> _6.0   929/  4297 (21.6%)  1149/  4284 (26.8%)
ALL PATIENTS  2033/10269 (19.8%)  2585/10267 (25.2%) 0.76 (0.72 − 0.81)
p<0.0001
0.6 0.8 1.0 1.2 1.4
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cancers) for reliable assessment, but an on-going meta-
analysis of individual patient data from all major statin
trials should be able to provide such information [35].
Individuals with a history of non-melanoma skin cancer
remained eligible for inclusion in HPS (although those
with a history of other cancers did not), and non-
melanoma skin cancer reported following randomisation
was to be considered separately from other cancers. Dur-
ing the 5-year scheduled treatment period, there were
more reports of non-melanoma skin cancer among the
simvastatin-allocated participants (243 [2.4%] vs 202
[2.0%]: RR 1.20 [0.99–1.44]), only one of which was
associated with death. This difference is not convention-
ally significant (p = 0.06), even before allowing for the
multiple comparisons involved. Moreover, it did not
appear to reflect a clear excess in either basal cell carcino-
mas (124 vs 99; RR 1.24 [0.96–1.61]; p = 0.1) or in squa-
mous cell carcinomas (137 vs 122; RR 1.12 [0.87–1.42]; p
= 0.4). Nor did this slight excess of non-melanoma skin
cancer become more apparent with more prolonged treat-
ment, as might be expected if it was causally related.
Indeed, the excess was observed largely during years 1 & 2
(107 [1.0%] vs 76 [0.7%]), with little apparent difference
during years 3 & 4 (91 [0.9%] vs 86 [0.9%]) or years 5+
(45 [0.5%] vs 40 [0.4%]).
Discussion
The large size of the Heart Protection Study, its prospec-
tive randomised design and the inclusion of a broad range
of participants allow it to assess reliably both the efficacy
and the safety of cholesterol lowering in a variety of differ-
ent circumstances. The present results demonstrate that
lowering LDL cholesterol by about 1 mmol/L (38 mg/dL)
for 5 years with a statin reduces the rate of death from vas-
cular causes by about one-sixth, with no apparent adverse
effect on non-vascular mortality or morbidity. This pro-
portional reduction in vascular mortality was remarkably
Effect of simvastatin allocation on non-vascular death in participants subdivided by presenting features Figure 7
Effect of simvastatin allocation on non-vascular death in participants subdivided by presenting features. Symbols 
and conventions as in Figures 1 & 5.
Presenting Simvastatin Placebo Death rate ratio Heterogeneity
feature -allocated -allocated (95% CI) p-value
Gender
Male   449/  7727 (5.8%)   465/  7727 (6.0%) p=0.8
Female    98/  2542 (3.9%)   105/  2540 (4.1%)
Age (years)
<65   142/  4903 (2.9%)   145/  4936 (2.9%) p=0.9
> _65 to <70   142/  2447 (5.8%)   157/  2444 (6.4%)
> _70   263/  2919 (9.0%)   268/  2887 (9.3%)
LDL cholesterol (mmol/L)
<3.0   199/  3389 (5.9%)   200/  3404 (5.9%) p=0.8
> _3.0 to <3.5   128/  2549 (5.0%)   139/  2514 (5.5%)
> _3.5   220/  4331 (5.1%)   231/  4349 (5.3%)
Total cholesterol (mmol/L)
<5.0   131/  2030 (6.5%)   133/  2042 (6.5%) p=0.8
> _5.0 to <6.0   208/  3942 (5.3%)   211/  3941 (5.4%)
> _6.0   208/  4297 (4.8%)   226/  4284 (5.3%)
ALL PATIENTS   547/10269 (5.3%)   570/10267 (5.6%) 0.95 (0.85 − 1.07)
p=0.4
0.6 0.8 1.0 1.2 1.4
Simvastatin better Placebo betterBMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
Page 13 of 21
(page number not for citation purposes)
consistent among the different types of participant stud-
ied, including women as well as men, older as well as
younger individuals, and those who entered the study
with below average cholesterol concentrations. Further-
more, the lack of any significant hazard was also consist-
ent among the different types of participant, and there was
no suggestion of any adverse effects emerging with more
prolonged follow-up.
Consistent beneficial effects of cholesterol lowering on 
vascular mortality and morbidity
The prespecified analyses for assessing the benefits of sta-
tin allocation in different types of participant were to be
of major vascular and coronary events. Because much
larger numbers suffered at least one such event, analyses
of those outcomes can help interpret the observed effects
on the smaller numbers of deaths from vascular causes.
For example, the proportional reduction in vascular mor-
tality observed among the 5082 participating women was
very similar to that among the men. But since fewer
women took part and their absolute risk of vascular death
was somewhat lower, this result did not reach conven-
tional levels of statistical significance on its own (p =
0.08). Even so, the very definite and highly significant
reductions in major vascular events observed among the
participating women (figure 6) indicate that the reduction
in vascular death, and hence in all-cause mortality, among
the women is real [36,37]. Similarly, the highly significant
reductions in major vascular events in the elderly and
those with below average cholesterol concentrations at
baseline reinforce the consistent reductions in vascular
mortality of about one-sixth in these groups. Given the
two-thirds compliance during HPS, actual use of 40 mg
simvastatin daily in this population would lower LDL
cholesterol by about 1.5 mmol/L (57 mg/dL), and this
would probably reduce the vascular death rate by about
one quarter. Furthermore, the continued divergence in the
vascular death rate during successive years of follow-up
Effect of simvastatin allocation on all-cause mortality in participants subdivided by presenting features Figure 8
Effect of simvastatin allocation on all-cause mortality in participants subdivided by presenting features. Symbols 
and conventions as in Figures 1 & 5.
Presenting Simvastatin Placebo Death rate ratio Heterogeneity
feature -allocated -allocated (95% CI) p-value
Gender
Male  1102/  7727 (14.3%)  1245/  7727 (16.1%) p=0.8
Female   226/  2542 (8.9%)   262/  2540 (10.3%)
Age (years)
<65   365/  4903 (7.4%)   418/  4936 (8.5%) p=1.0
> _65 to <70   361/  2447 (14.8%)   413/  2444 (16.9%)
> _70   602/  2919 (20.6%)   676/  2887 (23.4%)
LDL cholesterol (mmol/L)
<3.0   440/  3389 (13.0%)   485/  3404 (14.2%) p=0.7
> _3.0 to <3.5   308/  2549 (12.1%)   364/  2514 (14.5%)
> _3.5   580/  4331 (13.4%)   658/  4349 (15.1%)
Total cholesterol (mmol/L)
<5.0   276/  2030 (13.6%)   303/  2042 (14.8%) p=0.8
> _5.0 to <6.0   479/  3942 (12.2%)   557/  3941 (14.1%)
> _6.0   573/  4297 (13.3%)   647/  4284 (15.1%)
ALL PATIENTS  1328/10269 (12.9%)  1507/10267 (14.7%) 0.87 (0.81 − 0.94)
p=0.0003
0.6 0.8 1.0 1.2 1.4
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(reinforced by the similar effect on major vascular events)
suggests that more prolonged statin therapy would pro-
duce even larger absolute reductions in vascular mortality.
Despite the proven benefits of statins in people with cor-
onary heart disease, it has been suggested that statins may
have adverse effects among people with overt heart failure
[31]. Only small numbers of participants died from heart
failure during HPS, but simvastatin allocation was associ-
ated with a marginally significant reduction in heart fail-
ure hospitalisations or deaths during the treatment
period. Patients with occlusive arterial disease or diabetes
who had coexistent heart failure were still eligible for the
study provided they were not breathless at rest. Although
the presence of heart failure at study entry was not
routinely recorded, ACE inhibitors were chiefly used for
heart failure or hypertension during the recruitment
period (1994–7), which predated evidence from the
HOPE trial of benefit in other circumstances [38]. Among
participants using ACE inhibitors at baseline, many of
whom were likely to have had heart failure, simvastatin
allocation significantly reduced the risk of major vascular
events (495 [24.9%] simvastatin vs 568 [28.5%] placebo;
RR 0.84 [0.75–0.95]; p = 0.006), and there was a non-sig-
nificant trend towards fewer vascular deaths (265 [13.3%]
vs 285 [14.3%]; RR 0.93 [0.78–1.09]; p = 0.4). These
results are not consistent with any substantial adverse
effect of statin therapy on heart failure, and suggest that
the beneficial effect on major vascular events is likely to
outweigh any small adverse effect that might exist.
Subsequent analyses of HPS based on baseline blood lev-
els of brain natriuretic peptide (which is a sensitive and
Table 3: Effect of simvastatin allocation on site-specific cancer incidence








Lung/larynx 171 (1.7%) 157 (1.5%) 1.08 (0.87 – 1.34)
Other 8 (0.1%) 10 (0.1%) 0.79 (0.32 – 2.00)
Subtotal: Respiratory 179 (1.7%) 167 (1.6%) 1.06 (0.86 – 1.31) 0.6
Gastrointestinal
Upper GI 74 (0.7%) 62 (0.6%) 1.18 (0.84 – 1.65)
Colon/rectum 114 (1.1%) 131 (1.3%) 0.86 (0.67 – 1.11)
Other 41 (0.4%) 33 (0.3%) 1.23 (0.78 – 1.94)
Subtotal: Gastrointestinal 228 (2.2%) 223 (2.2%) 1.01 (0.84 – 1.22) 0.9
Connective tissue
Female breast 38 (1.5%) 51 (2.0%) 0.74 (0.49 – 1.12)
Melanoma 17 (0.2%) 10 (0.1%) 1.66 (0.78 – 3.54)
Other 5 (0.0%) 7 (0.1%) 0.71 (0.23 – 2.20)
Subtotal: Connective tissue 60 (0.6%) 68 (0.7%) 0.87 (0.62 – 1.24) 0.4
Genitourinary
Renal 23 (0.2%) 22 (0.2%) 1.04 (0.58 – 1.86)
Bladder 74 (0.7%) 90 (0.9%) 0.81 (0.60 – 1.11)
Prostate 145 (1.9%) 145 (1.9%) 0.99 (0.79 – 1.25)
Gynaecological 19 (0.7%) 18 (0.7%) 1.05 (0.55 – 2.00)
Other 6 (0.1%) 6 (0.1%) 0.99 (0.32 – 3.08)
Subtotal: Genitourinary 259 (2.5%) 272 (2.6%) 0.94 (0.80 – 1.12) 0.5
Haematological
Leukaemia/lymphoma 42 (0.4%) 32 (0.3%) 1.30 (0.82 – 2.05)
Other 23 (0.2%) 23 (0.2%) 0.99 (0.55 – 1.76)
Subtotal: Haematological 64 (0.6%) 52 (0.5%) 1.22 (0.85 – 1.75) 0.3
Other & unspecified 54 (0.5%) 57 (0.6%) 0.94 (0.65 – 1.36) 0.7
ALL CANCERS* 814 (7.9%) 803 (7.8%) 1.00 (0.91 – 1.11) 0.9
* Prespecified that analyses of cancer incidence were to exclude non-melanoma skin cancer (243 [2.4%] simvastatin-allocated versus 202 [2.0%] 
placebo-allocated; p = 0.06).BMC Medicine 2005, 3:6 http://www.biomedcentral.com/1741-7015/3/6
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validated marker of heart failure [39]) should help further
to assess the effects of statin treatment in patients with
heart failure (as will on-going trials in such individuals
[40]).
The significant 13% (SE 4) reduction in all-cause mortal-
ity observed in HPS reflects the combined impact in this
high risk population of the significant 17% (4) reduction
in vascular mortality produced by lowering LDL choles-
terol by 1 mmol/L and the lack of any significant effect on
deaths from non-vascular causes during 5 years of treat-
ment. Since the proportion of vascular to non-vascular
deaths will differ between populations, the observed
reduction in all-cause mortality is not readily generalisa-
ble to other situations, whereas the reduction in vascular
mortality may well be. Direct assessment of the effect of
cholesterol lowering on total mortality could also obscure
potentially important differences in the effects on cause-
specific mortality in particular circumstances [41]. Conse-
quently, the separate analyses of vascular and non-vascu-
lar mortality (and morbidity) presented here provide both
more sensitive and more generalisable evidence, not only
of any beneficial effects of cholesterol-lowering statin
treatment but also of any hazards in particular
circumstances.
No evidence of adverse effects of cholesterol-lowering on 
non-vascular mortality or morbidity
HPS involved much larger numbers of non-vascular
deaths, cancers and other serious non-vascular outcomes
than any previous cholesterol-lowering study, as well as
including large numbers of participants with relatively
low cholesterol concentrations. It can, therefore, help
address remaining uncertainty as to whether associations
in non-randomised observational studies between lower
total cholesterol concentrations (e.g. <4 mmol/L) and
higher rates of particular non-vascular conditions are
causal or, instead, due to confounding or reverse
causation [3,4]. Reassuringly, among the 20,000 partici-
pants in HPS, lowering total cholesterol by an average of
1.2 mmol/L (46 mg/dL) for 5 years did not appear to have
any adverse effect on non-vascular mortality or morbidity.
Although there were too few deaths from some particular
causes to assess the effects of cholesterol-lowering directly,
the results for relevant non-fatal outcomes were of help in
overcoming these limitations. For example, despite
inverse associations in observational studies between cho-
lesterol concentrations and respiratory mortality [1,2], the
randomised evidence from HPS does not indicate any
adverse effect of lowering cholesterol on either respiratory
mortality or on the much larger number of hospitalisa-
tions for fatal or non-fatal respiratory illness (or, indeed,
on lung function). Similarly, the apparent lack of any
adverse effect in HPS for deaths from cancer, haemor-
rhagic stroke, liver or renal disease is reinforced by the
results for the larger numbers of related non-fatal
outcomes.
Some non-randomised observational studies have found
lower cholesterol concentrations to be associated with
higher mortality in the elderly [32,33], and there has been
uncertainty about the effectiveness of cholesterol-lower-
ing in older people [37]. In HPS, however, allocation to
cholesterol-lowering statin therapy not only reduced vas-
cular (and total) mortality among 5806 participants aged
70 or over at presentation, but there was also no apparent
Effect of simvastatin allocation on incidence of first cancer by period of follow-up Figure 9
Effect of simvastatin allocation on incidence of first cancer by period of follow-up. Symbols and conventions as in 
Figure 1. Excludes non-melanoma skin cancer.
Year of Events/people (& %) Event rate ratio & 95% CI
follow-up Simvastatin Placebo (Simvastatin:Placebo)
1 & 2   274/10269 (2.7%)   257/10267 (2.5%)
3 & 4   316/  9730 (3.2%)   343/  9650 (3.6%)
5+   224/  9058 (2.5%)   203/  8890 (2.3%)
ALL FOLLOW-UP   814/10269 (7.9%)   803/10267 (7.8%) 1.00 (0.91 - 1.11)
p=0.9
0.6 0.8 1.0 1.2 1.4
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increase in non-vascular mortality. More recently, a ran-
domised trial reported a marginally significant excess with
statin allocation among the 444 patients aged 70–82 at
presentation who developed cancer during 3 years of
treatment [34]. But that result may well represent a chance
finding, since no significant excess was seen with statin
allocation among the 674 HPS participants aged at least
70 at presentation who developed cancer during 5 years
follow-up, nor has any such excess been reported from the
other large statin trials [23]. Chance may also explain the
slight (but non-significant) excess of non-melanoma skin
cancers observed during HPS, since that excess was largely
confined to the early years of the study, was seen with
both squamous and basal cell carcinomas, and is not sup-
ported by published data from other major statin trials
excluding HPS (724 [4.2%] statin vs 699 [4.1%] placebo;
odds ratio 1.04; 95% CI 0.93–1.15; p = 0.5)
[12,17,22,42].
If lowering cholesterol really did have adverse effects on
non-vascular mortality or morbidity [43] then this might
be more apparent either among participants who entered
HPS with below average cholesterol levels (and so had
their cholesterol concentration reduced to very low levels)
or after more prolonged exposure to treatment during the
later years of follow-up. But even among the 4072 partic-
ipants whose pretreatment total cholesterol was below 5.0
mmol/L, lowering total cholesterol to an average of 3.5
mmol/L (133 mg/dL) for 5 years was not associated with
any excess of non-vascular mortality or morbidity. Nor
did any adverse effects begin to emerge with more pro-
longed treatment and follow-up during the trial. Never-
theless, cancer and other risks may take many years to
become manifest, and extended follow-up for mortality
and morbidity in HPS (as well as in some other statin tri-
als [44]) will help assess any longer term effects.
Effect of simvastatin allocation on cancer incidence in participants subdivided by presenting features Figure 10
Effect of simvastatin allocation on cancer incidence in participants subdivided by presenting features. Symbols 
and conventions as in Figures 1 & 5. Excludes non-melanoma skin cancer.
Presenting Simvastatin Placebo Event rate ratio Heterogeneity
feature -allocated -allocated (95% CI) p-value
Gender
Male   662/  7727 (8.6%)   656/  7727 (8.5%) p=0.8
Female   152/  2542 (6.0%)   147/  2540 (5.8%)
Age (years)
<65   248/  4903 (5.1%)   237/  4936 (4.8%) p=0.6
> _65 to <70   221/  2447 (9.0%)   237/  2444 (9.7%)
> _70   345/  2919 (11.8%)   329/  2887 (11.4%)
LDL cholesterol (mmol/L)
<3.0   265/  3389 (7.8%)   292/  3404 (8.6%) p=0.1
> _3.0 to <3.5   194/  2549 (7.6%)   204/  2514 (8.1%)
> _3.5   355/  4331 (8.2%)   307/  4349 (7.1%)
Total cholesterol (mmol/L)
<5.0   169/  2030 (8.3%)   193/  2042 (9.5%) p=0.1
> _5.0 to <6.0   298/  3942 (7.6%)   310/  3941 (7.9%)
> _6.0   347/  4297 (8.1%)   300/  4284 (7.0%)
ALL PATIENTS   814/10269 (7.9%)   803/10267 (7.8%) 1.00 (0.91 − 1.11)
p=0.9
0.6 0.8 1.0 1.2 1.4
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Effect of simvastatin allocation on site-specific cancers subdivided by age and total cholesterol at study entry Figure 11
Effect of simvastatin allocation on site-specific cancers subdivided by age and total cholesterol at study entry. 
Symbols and conventions as in Figures 1 & 5. Excludes non-melanoma skin cancer.
Cancer site by age (years) Simvastatin Placebo Event rate ratio Heterogeneity
& total cholesterol (mmol/L) -allocated -allocated (95% CI) p-value
(10,269) (10,267)
Respiratory
Age   <70   101 (1.4%)    95 (1.3%) p=1.0
          >           _70    78 (2.7%)    72 (2.5%)
Chol <5.0    36 (1.8%)    35 (1.7%) p=0.9
         >          _5.0   143 (1.7%)   132 (1.6%)
Any respiratory   179 (1.7%)   167 (1.6%) 1.06 (0.86 - 1.31) 
Gastrointestinal
Age   <70   145 (2.0%)   131 (1.8%) p=0.2
          >           _70    83 (2.8%)    92 (3.2%)
Chol <5.0    51 (2.5%)    62 (3.0%) p=0.2
         >          _5.0   177 (2.1%)   161 (2.0%)
Any gastrointestinal   228 (2.2%)   223 (2.2%) 1.01 (0.84 - 1.22) 
Genitourinary
Age   <70   138 (1.9%)   156 (2.1%) p=0.4
          >           _70   121 (4.1%)   116 (4.0%)
Chol <5.0    52 (2.6%)    65 (3.2%) p=0.3
         >          _5.0   207 (2.5%)   207 (2.5%)
Any genitourinary   259 (2.5%)   272 (2.6%) 0.94 (0.80 - 1.12) 
All others
Age   <70   101 (1.4%)   109 (1.5%) p=0.3
          >           _70    73 (2.5%)    61 (2.1%)
Chol <5.0    38 (1.9%)    44 (2.2%) p=0.4
         >          _5.0   136 (1.7%)   126 (1.5%)
Any other   174 (1.7%)   170 (1.7%) 1.01 (0.82 - 1.25) 
ALL CANCERS (except 
non-melanoma skin)
  814 (7.9%)   803 (7.8%) 1.00 (0.91 - 1.11) 
0.6 0.8 1.0 1.2 1.4
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Efficacy and safety of large cholesterol reductions
As might be expected from the approximately log-linear
association in observational studies between vascular dis-
ease risk and cholesterol concentrations [2,5], a 1 mmol/
L LDL cholesterol reduction in HPS from about 4 mmol/
L to about 3 mmol/L (i.e. about 155 to about 116 mg/dL)
reduced the risks of vascular death by about one sixth and
of other major vascular events by about one-quarter, and
so too did reducing it from about 3 mmol/L to about 2
mmol/L (i.e. about 116 to about 77 mg/dL), without any
evidence of adverse effects. Recently, a randomised study
of more intensive statin treatment versus a standard regi-
men in 4162 patients found that lowering LDL cholesterol
to 1.6 mmol/L [62 mg/dL] rather than to 2.5 mmol/L [95
mg/dL] for about 18 months produced a 16% (95% CI 5–
26) reduction in major vascular events [45]. These find-
ings indicate that any thresholds below which lowering
LDL cholesterol does not safely reduce vascular disease
risk are at much lower concentrations (e.g. below 2
mmol/L [77 mg/dL] of LDL cholesterol or 3.5 mmol/L
[135 mg/dL] of total cholesterol) than are typically seen in
Western populations. Several large-scale trials that are cur-
rently assessing more intensive statin regimens [46-48]
will provide further information as to whether even more
substantial cholesterol reductions are not only effective at
lowering vascular disease risk but also safe.
Conclusion
Based on large numbers of deaths and other relevant out-
comes, the present results show that lowering LDL
cholesterol by an average of 1 mmol/L produces substan-
tial reductions in vascular (and, hence, all-cause) mortal-
ity in a wide range of individuals at increased risk of
occlusive arterial disease (as well as reducing their risks of
heart attacks, strokes and revascularisation procedures).
These results also provide considerable reassurance that
lowering total cholesterol concentrations by more than 1
mmol/L for an average of 5 years does not produce
adverse effects on non-vascular mortality or cancer inci-
dence, even among those who had their cholesterol con-
centrations reduced to very low levels. Indirectly, this
observation provides some reassurance about the likely
efficacy and safety of the more intensive cholesterol-low-
ering achievable with higher-dose or newer statins, and
with combinations of standard statin doses and drugs
acting through other pathways (such as resins or choles-
terol absorption inhibitors). The present results provide
further evidence of the benefits and safety of using statin
therapy routinely in anyone (irrespective of their initial
cholesterol concentration or other factors, such as age or
gender) in whom a reduction in their vascular disease risk
of about one third would be considered worthwhile.
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